EFM
VTGN icon

E Fund Management’s VistaGen Therapeutics VTGN Stock Holding History

E Fund Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-540
Closed -$32K – 362
2021
Q4 		$32K Buy
540
+81
+18% +$5.27K ﹤0.01% 299
2021
Q3 		$38K Buy
+459
New +$39.9K ﹤0.01% 269

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

E Fund Management's VTGN Position: Q1 2022 in Review

E Fund Management sold out of VistaGen Therapeutics (VTGN) in Q1 2022, closing a stake of 540 shares — an estimated $32K sold.

E Fund Management first reported a position in VTGN in Q3 2021 and held it in 2 quarters. The position peaked at $38K in Q3 2021. 116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

  • E Fund Management reported no remaining VistaGen Therapeutics position as of Q1 2022 after selling out during the quarter.
  • E Fund Management sold 540 VistaGen Therapeutics shares in Q1 2022, an estimated $32K.
  • E Fund Management first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 2 quarters.
  • E Fund Management's VistaGen Therapeutics position peaked at $38K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on E Fund Management's 13F filing for Q1 2022, filed 12 May 2022.